A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Inclusion Criteria: * Participant must be 18 to 75 years of age inclusive. * BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity. * A stable, self-reported body weight for 3 months prior to screening. * Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. * Capable of giving signed informed consent. Exclusion Criteria: * History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk. * History or presence of GI, renal, hepatic disease. * Previous or planned bariatric surgery or fitting of a weight loss device. * Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome. * History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control. * HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L). * Significant gastric and hepatobiliary disease. * History of acute or chronic pancreatitis or pancreatic amylase or lipase \> 2 × ULN at screening. * History of psychosis or bipolar disorder. * History of major depressive disorder within the 2 years prior to screening or depression. * Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening. * Vulnerable populations